11:27 AM EST - Lobe Sciences Ltd : Today announced it has entered into an exclusive agreement with iNGENu Pty Ltd., an Australian based Contract Research Organization, to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131. Lobe Sciences Ltd
shares C.LOBE are trading unchanged at $0.06.
